A detailed history of Hrt Financial LP transactions in Xencor Inc stock. As of the latest transaction made, Hrt Financial LP holds 62,190 shares of XNCR stock, worth $1.29 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
62,190
Holding current value
$1.29 Million
% of portfolio
0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$15.7 - $21.65 $976,383 - $1.35 Million
62,190 New
62,190 $1.25 Million
Q4 2023

Feb 09, 2024

SELL
$16.53 - $21.42 $131,099 - $169,882
-7,931 Reduced 27.02%
21,421 $454,000
Q3 2023

Nov 13, 2023

BUY
$20.08 - $25.39 $589,388 - $745,247
29,352 New
29,352 $591,000
Q4 2022

Feb 10, 2023

BUY
$24.79 - $30.86 $119,091 - $148,251
4,804 Added 21.29%
27,366 $712,000
Q3 2022

Nov 14, 2022

BUY
$24.62 - $32.44 $555,476 - $731,911
22,562 New
22,562 $586,000
Q2 2022

Aug 12, 2022

SELL
$19.74 - $29.01 $386,706 - $568,305
-19,590 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$26.68 - $41.63 $33,936 - $52,953
1,272 Added 6.94%
19,590 $522,000
Q4 2021

Feb 14, 2022

SELL
$33.67 - $43.44 $353,770 - $456,424
-10,507 Reduced 36.45%
18,318 $734,000
Q3 2021

Nov 15, 2021

SELL
$30.65 - $35.68 $298,684 - $347,701
-9,745 Reduced 25.27%
28,825 $941,000
Q2 2021

Aug 16, 2021

BUY
$34.33 - $44.68 $810,805 - $1.06 Million
23,618 Added 157.96%
38,570 $1.33 Million
Q1 2021

May 17, 2021

BUY
$40.81 - $53.88 $610,191 - $805,613
14,952 New
14,952 $643,000
Q1 2020

May 15, 2020

SELL
$20.69 - $37.79 $195,313 - $356,737
-9,440 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$32.75 - $41.43 $309,160 - $391,099
9,440 New
9,440 $324,000

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.23B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.